Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THALIDOMIDE vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Immunomodulatory and antiangiogenic action: TNF-alpha inhibitor, alters adhesion molecule expression, inhibits angiogenesis via VEGF/FGF inhibition, modulates T-cell co-stimulation and NF-κB activity.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Newly diagnosed multiple myeloma (in combination with dexamethasone),Leprosy (erythema nodosum leprosum)
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
100 mg orally once daily, preferably at bedtime to minimize sedation; maximum dose 400 mg daily for multiple myeloma or erythema nodosum leprosum.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life is approximately 5-7 hours in healthy adults, but may be prolonged to 7-10 hours in patients with renal impairment or advanced age.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Primarily non-enzymatic hydrolysis in plasma; minor CYP2C19-mediated hydroxylation.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Thalidomide is primarily eliminated by nonenzymatic hydrolysis in plasma and tissues; renal excretion accounts for <1% of unchanged drug; metabolites are excreted renally (~90%) and fecally (~10%).
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Approximately 55-65% bound to albumin and alpha-1-acid glycoprotein.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Volume of distribution is approximately 1.2 L/kg (range 0.8-1.5 L/kg), indicating extensive distribution into body tissues.
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral bioavailability is approximately 90-100% (absolute bioavailability).
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
No dosage adjustment required for renal impairment. Thalidomide is minimally renally excreted; however, use with caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh Class A: 100 mg daily. Child-Pugh Class B: Reduce to 50 mg daily or 100 mg every other day. Child-Pugh Class C: Not recommended due to lack of safety data.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Not approved for use in children; safety and efficacy not established. In investigational settings, 2-5 mg/kg/day orally divided every 12 hours, with a maximum of 100 mg/day.
Not approved for pediatric patients <18 years; safety and efficacy not established.
No specific dose adjustment, but start at low end of dosing range (50-100 mg daily) due to increased risk of sedation, constipation, and peripheral neuropathy. Monitor renal function, though no dose adjustment required.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
THALIDOMIDE IS CONTRAINDICATED IN PREGNANCY (CATEGORY X). Severe birth defects (phocomelia, other fetal anomalies) and fetal death. Must not be used by women who are pregnant or may become pregnant. Also contraindicated in sexually active women of childbearing potential unless using two reliable forms of contraception. Male patients must use latex condom during sexual contact with pregnant or childbearing-potential women. [See REMS program]
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Thromboembolism (DVT/PE) - increased risk with concurrent dexamethasone. Severe peripheral neuropathy (monitor for paresthesias). Neutropenia, thrombocytopenia. Dizziness, somnolence. Hypersensitivity reactions (angioedema, Stevens-Johnson syndrome). Bradycardia, syncope. Increased LFTs. Seizures. Amyloid deposition. Angioedema. Increases risk of hepatotoxicity. Use in renal/hepatic impairment with caution.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Pregnancy (Category X) - fetal toxicity. Women of childbearing potential not using two forms of contraception. Men not using latex condom. Hypersensitivity to thalidomide. Use with drugs that cause peripheral neuropathy. Severe neutropenia (ANC < 750/μL).
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Avoid grapefruit juice (may increase exposure). No specific food restrictions otherwise.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Thalidomide is contraindicated in pregnancy. First trimester exposure causes severe limb defects (phocomelia, amelia), ear anomalies, ocular defects, and cardiac malformations in up to 50% of exposed fetuses. Second and third trimester exposure risks fetal growth restriction and neurodevelopmental effects. No safe trimester exists.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Thalidomide is excreted in human milk; M/P ratio is approximately 0.5. Breastfeeding is contraindicated due to potential adverse effects in the infant, including sedation and neutropenia.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No dose adjustment studies in pregnancy exist because thalidomide is contraindicated. Pharmacokinetic changes in pregnancy (e.g., increased clearance, altered distribution) are expected but dose adjustments should not be attempted; alternative therapy must be used.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Strict REMS program required due to teratogenicity; screen for pregnancy before and during therapy. Monitor for thromboembolism, neuropathy, and bradycardia. Dose reduction needed in renal impairment. Can cause tumor lysis syndrome in multiple myeloma.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Never use during pregnancy – can cause severe birth defects.,Women must use two reliable contraceptives and undergo monthly pregnancy tests.,Men must use condoms during sexual activity with a pregnant woman or a woman who could become pregnant.,Avoid blood donation while on therapy and for 4 weeks after stopping.,Report numbness, tingling, drowsiness, or rash immediately.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
"Thalidomide, a sedative-hypnotic with central nervous system (CNS) depressant properties, can additively enhance the CNS-depressant effects of tiagabine, an anticonvulsant that potentiates GABAergic neurotransmission. This combination increases the risk of excessive sedation, dizziness, psychomotor impairment, and respiratory depression. Patients may experience compounded neurological effects, leading to reduced alertness and increased fall risk, particularly during initiation or dose escalation."
"Thalidomide, a known central nervous system depressant, can potentiate the sedative effects of fluticasone propionate, particularly when administered at high doses or via inhalation. This additive CNS depression may lead to increased sedation, dizziness, and impairment of cognitive or motor function, posing risks for falls or accidents. Patients should be warned against driving or operating heavy machinery until the combined effects are known."
"Thalidomide, an immunomodulatory agent, may antagonize the laxative effect of picosulfuric acid by reducing gastrointestinal motility through its anticholinergic-like properties and potential to cause constipation. This interaction could lead to decreased effectiveness of picosulfuric acid in promoting bowel evacuation, potentially resulting in inadequate bowel preparation for procedures or incomplete relief of constipation. Clinically, patients may experience reduced stool output or delayed onset of action, requiring alternative or additional laxative therapy."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THALIDOMIDE vs ABSTRAL, answered by our medical review team.
THALIDOMIDE is a Immunomodulatory Agent that works by Immunomodulatory and antiangiogenic action: TNF-alpha inhibitor, alters adhesion molecule expression, inhibits angiogenesis via VEGF/FGF inhibition, modulates T-cell co-stimulation and NF-κB activity.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THALIDOMIDE and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THALIDOMIDE is: 100 mg orally once daily, preferably at bedtime to minimize sedation; maximum dose 400 mg daily for multiple myeloma or erythema nodosum leprosum.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THALIDOMIDE and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THALIDOMIDE is classified as Category D/X. Thalidomide is contraindicated in pregnancy. First trimester exposure causes severe limb defects (phocomelia, amelia), ear anomalies, ocular defects, and cardiac malformations in u. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.